|Traded as||TYO: 4568
TOPIX 100 Component
Nikkei 225 Component
|Founded||Tokyo, Japan (2005) (by merger)|
|Headquarters||Daiichi Sankyo Building A/B 3-5-1, Nihonbashi-honcho, Chūō-ku, Tokyo 103-8426, Japan|
|Key people||Takashi Shoda, Chairman
Joji Nakayama, (CEO and President)
|Revenue||JPY) (FY 2012)|
|Net income||JPY) (FY 2012)|
|Employees||32,229 (as of December 2013)|
Daiichi Sankyo Company, Limited (第一三共株式会社 Daiichi Sankyō Kabushiki-kaisha?) is a global pharmaceutical company and the second largest pharmaceutical company in Japan. It achieved JPY 970 billion in revenue in 2010 and is currently ranked number 17 in world sales. Its headquarters is based in Tokyo. The company also owns the American biotechnology company Plexxikon, the German biotechnology company U3 and Ranbaxy Laboratories in India. Daiichi Sankyo is the producer of Benicar (Olmesartan), an angiotensin II receptor antagonist and top selling drug in the U.S. with total sales of USD 2.7 billion.
Daiichi Sankyo, Inc. (DSI) began operating in the U.S. in 2006. It is the U.S. subsidiary of Daiichi Sankyo, Company, Limited and a member of the Daiichi Sankyo Group. The organization, which includes U.S. commercial operations and global clinical development (Daiichi Sankyo Pharma Development), is headquartered in New Jersey.
Daiichi Sankyo Company, Limited is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA) and of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA).
In 2009, the highly respected magazine R&D Direction honoured Daiichi Sankyo with its "Best Cardiovascular Pipeline Award".
Daiichi Sankyo was established in 2005 through the merger of Sankyo Company, Limited (三共株式会社 Sankyō Kabushiki Kaisha?) and Daiichi Pharmaceutical Company, Limited (第一製薬株式会社 Daiichi Seiyaku Kabushiki Kaisha?), which were century-old pharmaceutical companies based in Japan.
On April 4, 2011 Daiichi Sankyo completed the acquisition of Plexxikon, a Berkeley, California-based pharmaceutical start-up company for $805 Million and an additional $130 Million in milestone payments, pending on the success of Vemurafenib (Plexxikon’s lead program) an oral, novel drug that targets the oncogenic BRAF mutation present in about half of melanoma cancers and about eight percent of all solid tumors. Daiichi Sankyo is retaining US co-promotion right of the (Roche licensed) drug. 
Select mid-stage and late-stage investigational candidates in Daiichi-Sankyo's pipeline include: